Short Description: An Open-Access, Peer-Reviewed, Google Scholar & CAS (ACS) indexed, Cabells WHITE-LISTED journal, publishing scholarly articles in Biology, Medicine, Agriculture & Allied Sciences.
E-ISSN: 2378-654X
P-ISSN:
Publisher: HATASO - SynergyGlobal
Institute:
Address: Plot No. 15, Ground Floor, 3rd Cross, Balaji Nagar, Oulgaret
City: Puducherry
State: Puducherry
Country: India
ZIP: 605010
Phone:
Email: [email protected]
10.18639/RABM.2025.9800045
Original Research Article
Aug 12, 2025
There is a lack of research on low-risk HPV infections like genital warts among vulnerable women, especially their HIV serology, because research focuses on high-risk strains of HPV associated with cervical cancer. The interplay between genital warts, HIV status, and sociocultural factors is crucial to understanding targeted prevention to alleviate the burden of genital warts in vulnerable populations. In this study, we investigate the prevalence and risk factors of genital warts among women with HIV serostatus. Women seeking gynecological consultation at a public hospital in Nigeria were studied cross-sectionally. A survey and medical records were used to collect data, which was then analyzed using SPSS 18.0. The majority of the women who had genital warts (63.33%) were HIV positive. For the first time, 67% of these women sought gynecological consultations for genital warts. Women with HIV were more likely to experience papule genital warts, while women without HIV were more likely to experience acuminate warts. Moreover, HIV-positive women with multiple sexual partners were found to have an increased risk of developing genital warts. Self-medication (75%) and traditional medicine (85%) were also prevalent. Healthcare-seeking behavior must be enhanced, early detection and treatment must be facilitated, and HIV and genital warts must be alleviated by addressing socio-cultural barriers. Traditional medicine should be integrated into healthcare systems, and efforts to raise awareness should be prioritized.
10.18639/RABM.2025.9800044
Original Research Article
Jun 02, 2025
This paper explores the growth of biological medicine in the South African pharmaceutical sector for the period 2019 to 2023. The study analysis revenue trends over time and investigates challenges experienced and suggests possible solutions. Results show that small-molecules and biologicals follow a similar pattern with a major peak in 2021 and a decline thereafter, with total revenue for small molecules much higher than for biologicals over these years. Biologicals generally had growth through 2021, then experienced a significant decline in sales and growth in the following years. To promote the growth of biological medicines in South Africa, it is vital to streamline regulatory frameworks for quicker approval of biologicals and biosimilars while ensuring safety and efficacy. Implementing affordable pricing strategies and fostering collaboration between public entities, pharmaceutical companies, and insurers will enhance reimbursement policies. Additionally, increasing educational initiatives for healthcare providers will improve awareness and prescribing practices. Investing in local manufacturing can reduce costs and create jobs, while raising awareness of biosimilars as cost-effective alternatives will further boost their adoption and accessibility.
10.18639/RABM.2025.9800043
Conference Proceedings
Feb 27, 2025
Proceedings of the National Conference on “Advances in Biological Sciences: Molecules to Organisms", organized by the Department of Zoology, AMU, Aligarh, India, from December 28 to 29, 2024.
